Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis

doi:10.19982/j.issn.1000-6621.20240127

Abstract

Abstract:

Objective: This study aims to delineate the clinical presentations, radiographic features, and laboratory findings of patients co-infected with the novel coronavirus (COVID-19) and pulmonary tuberculosis, with a particular focus on assessing the prognostic implications of tuberculosis in the context of COVID-19 infection. Methods: The cohort comprised 140 patients admitted to Hunan Provincial Chest Hospital between December 2022 and January 2023 with confirmed COVID-19 infection. This group included 57 patients with isolated COVID-19 infection and 83 patients with concurrent pulmonary tuberculosis, of which 32 were diagnosed with drug-resistant tuberculosis. Comprehensive data on demographic characteristics, clinical manifestations, laboratory diagnostics, and outcomes were systematically gathered for analysis. A case-control study design was utilized. Initially, subjects were stratified into either the isolated COVID-19 group or the COVID-19 with tuberculosis co-infection group, facilitating a comparative analysis of demographic data, clinical manifestations, laboratory outcomes, and prognostic data. Subsequently, patients within the tuberculosis co-infection group were further categorized based on drug-resistance status, sputum test results, and treatment classification to refine the analytical depth. Kaplan-Meier survival analysis was employed to delineate the survival disparities between the groups. This analysis was instrumental in further identifying and evaluating the risk factors that may influence the prognosis of patients afflicted with both COVID-19 and pulmonary tuberculosis. Results: Patients co-infected with COVID-19 and tuberculosis exhibited a notably poorer prognosis, as evidenced by prolonged chest imaging recovery times (median (interquartile range, IQR)) of 8.5 (7.0, 11.5) days, compared to 7.0 (5.0, 10.0) days in the COVID-19-only group, achieving statistical significance (U=785.000, P=0.049). Furthermore, initial symptoms in the co-infected cohort were less typical, with fever presenting in only 38.6% (32/83) of cases, significantly lower than the 56.1% (32/57) observed in the COVID-19-only group (χ²=4.311, P=0.040). Radiographic findings between the groups revealed marked differences. In the isolated COVID-19 group, ground glass opacities were predominant, appearing in 52.6% (30/57) of cases, significantly exceeding the 21.7% (18/83) observed in the tuberculosis co-infected group (χ²=14.362, P<0.001). Conversely, the imaging profiles in the co-infected group were notably more complex, with patchy opacities and linear streaks being the most prevalent, identified in 91.6% (76/83) of cases—substantially higher than the 56.1% (32/57) and 28.1% (16/57) seen in the COVID-19-only group, with statistically significant differences (χ²=24.052 and 60.471, P<0.001 respectively). In patients with concurrent COVID-19 and tuberculosis, lymphocyte counts were significantly reduced at 1.0×10⁹/L (IQR: 0.7×10⁹/L to 1.6×10⁹/L), compared to 1.3×10⁹/L (IQR: 0.9×10⁹/L to 2.0×10⁹/L) in those with COVID-19 alone (U=1736.000, P=0.015). Similarly, white blood cell counts were lower in the co-infected group, recorded at 5.0×10⁹/L (IQR: 3.8×10⁹/L to 7.1×10⁹/L), versus 6.0×10⁹/L (IQR: 4.8×10⁹/L to 7.9×10⁹/L) in the COVID-19 only group, a statistically significant difference (U=1800.000, P=0.024). Neutrophil counts further supported these findings, being lower at 3.3×10⁹/L (IQR: 2.2×10⁹/L to 4.7×10⁹/L) compared to 3.6×10⁹/L (IQR: 3.0×10⁹/L to 5.2×10⁹/L) in patients with only COVID-19 (U=1865.000, P=0.049). Moreover, cytotoxic T cells (CD3⁺CD8⁺) counts were markedly reduced in the co-infected group at 344.2/μl (IQR: 239.6 to 457.3/μl), significantly lower than 567.6/μl (IQR: 437.8 to 618.6/μl) observed in the COVID-19 group (U=74.000, P=0.009). Survival analysis identified sputum positivity as a significant prognostic risk factor in these patients. Conclusion: Patients co-infected with COVID-19 and pulmonary tuberculosis experienced prolonged hospitalization and delayed recovery in chest imaging. Notably, those with sputum-positive pulmonary tuberculosis had significantly poorer prognostic outcomes.

Key words: Tuberculosis, pulmonary, Coronavirus infections, Comorbidity, Disease characteristics, Prognosis

CLC Number:

R521
R563

Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698. doi: 10.19982/j.issn.1000-6621.20240127

Figures/Tables 9

特征	合计 (140例)	新冠组 (57例)	新冠合并结核组 (83例)	统计检验值	P值
年龄(岁,$\bar{x}±s$)	61.3±16.9	64.8±17.6	58.9±16.1	t=2.080	0.039
性别[例(构成比,%)]				χ²=8.667	0.003
男性	89(63.6)	28(49.1)	61(73.5)
女性	51(36.4)	29(50.9)	22(26.5)
体质量指数($\bar{x}±s$)	21.9±4.0	23.8±3.7	20.7±3.8	t=4.721	<0.001
吸烟[例(构成比,%)]				χ²=7.851	0.006
是	48(34.3)	12(21.1)	36(43.4)
否	92(65.7)	45(78.9)	47(56.6)
饮酒[例(构成比,%)]				χ²=0.760	0.383
是	19(13.6)	6(10.5)	13(15.7)
否	121(86.4)	51(89.5)	70(84.3)
预后情况[例(构成比,%)]				χ²=0.002	0.961
改善	135(96.4)	55(96.5)	80(96.4)
恶化	5(3.6)	2(3.5)	3(3.6)
住院时间[d,M(Q₁,Q₃)]	10.0(7.0,13.0)	9.5(6.0,12.0)	10.0(7.0,13.0)	U=2398.000	0.251
CT影像学恢复时间[d,M(Q₁,Q₃)]	7.0(5.0,11.0)	7.0(5.0,10.0)	8.5(7.0,11.5)	U=785.000	0.049
合并症[例(发生率,%)]
尘肺	6(5.2)	0(0.0)	6(7.6)	χ²=1.617	0.203
慢性阻塞性肺疾病	57(49.1)	19(51.4)	38(48.1)	χ²=0.107	0.744
肿瘤	5(4.2)	3(7.7)	2(2.5)	χ²=0.678	0.410
糖尿病	31(25.6)	7(17.1)	24(30.0)	χ²=2.377	0.123
心血管疾病	61(50.0)	27(62.8)	34(43.0)	χ²=4.346	0.037
慢性肝病	6(5.2)	1(2.7)	5(6.3)	χ²=0.139	0.710
慢性肾病	1(0.9)	0(0.0)	1(1.3)		1.000^a
首发症状[例(发生率,%)]
发热	64(45.7)	32(56.1)	32(38.6)	χ²=4.211	0.040
咳嗽	125(89.3)	53(93.0)	72(86.7)	χ²=1.373	0.241
呼吸困难	63(45.0)	26(45.6)	37(44.6)	χ²=0.015	0.904
肌肉酸痛	24(17.1)	9(15.8)	15(18.1)	χ²=0.124	0.725
咽痛	20(14.3)	8(14.0)	12(14.5)	χ²=0.005	0.944
胸闷	21(15.0)	9(15.8)	12(14.5)	χ²=0.047	0.828
消化道症状	36(25.7)	12(21.1)	24(28.9)	χ²=1.094	0.296
皮肤症状	2(1.4)	0(0.0)	2(2.4)		0.514^a
CT影像学特征[例(发生率,%)]
磨玻璃影	48(34.3)	30(52.6)	18(21.7)	χ²=14.362	<0.001
斑片影	108(77.1)	32(56.1)	76(91.6)	χ²=24.052	<0.001
条索影	92(65.7)	16(28.1)	76(91.6)	χ²=60.471	<0.001
胸膜增厚	29(20.7)	4(7.0)	25(30.1)	χ²=10.982	0.001
结节	31(22.1)	7(12.3)	24(28.9)	χ²=5.424	0.020
淋巴结肿大	25(17.9)	3(5.3)	22(26.5)	χ²=10.396	0.001
累及双肺	112(80.0)	49(86.0)	63(75.9)	χ²=2.138	0.144
累及右肺	13(9.3)	5(8.8)	8(9.6)	χ²=0.030	0.862
累及左肺	15(10.7)	3(5.3)	12(14.5)	χ²=2.986	0.084
治疗方案[例(使用率,%)]
抗生素治疗	92(65.7)	47(82.5)	45(54.2)	χ²=11.961	0.001
中药治疗	81(57.9)	32(56.1)	49(59.0)	χ²=0.116	0.733
激素治疗	25(17.9)	16(28.1)	9(10.8)	χ²=6.837	0.009
激素治疗时间[d,M(Q₁,Q₃)]	6.0(4.0,8.0)	6.0(3.8,8.0)	6.0(4.0,11.0)	U=80.500	0.637
抗病毒治疗	24(17.1)	14(24.6)	10(12.0)	χ²=3.725	0.054
抗病毒治疗时间[d,M(Q₁,Q₃)]	7.0(7.0,7.0)	7.0(6.5,8.3)	7.0(5.5,12.3)	U=67.000	0.850
实验室检测指标
红细胞计数[×10¹²/L,M(Q₁,Q₃)]	4.2(3.8,4.6)	4.2(3.9,4.6)	4.1(3.7,4.5)	U=1941.000	0.124
血红蛋白(g/L,$\bar{x}±s$)	120.8±18.6	124.5±16.5	118.3±19.6	t=2.007	0.047
红细胞压积(%,$\bar{x}±s$)	36.1±5.3	37.4±4.7	35.2±5.5	t=2.488	0.014
血小板计数(×10⁹/L,$\bar{x}±s$)	215.5±92.7	223.5±95.8	210.1±90.7	t=0.831	0.407
淋巴细胞计数[×10⁹/L,M(Q₁,Q₃)]	1.1(0.8,1.7)	1.3(0.9,2.0)	1.0(0.7,1.6)	U=1736.000	0.015
白细胞计数[×10⁹/L,M(Q₁,Q₃)]	5.4(4.0,7.6)	6.0(4.8,7.9)	5.0(3.8,7.1)	U=1800.000	0.024
中性粒细胞计数[×10⁹/L, M(Q₁,Q₃)]	3.4(2.5,5.1)	3.6(3.0,5.2)	3.3(2.2,4.7)	U=1865.500	0.049
中性粒细胞百分比[%,M(Q₁,Q₃)]	63.4(54.6,74.3)	62.4(55.7,75.0)	64.1(52.8,73.8)	U=2264.500	0.798
CD3⁺CD4⁺细胞计数[个/μl, M(Q₁,Q₃)]	545.1(396.6,781.8)	703.7(535.3,800.6)	454.7(301.3,638.6)	U=107.000	0.142
CD3⁺CD4⁺细胞百分比[%, M(Q₁,Q₃)]	37.1(32.2,45.7)	36.4(32.1,44.6)	39.1(33.4,47.7)	U=172.000	0.523
CD3⁺CD8⁺细胞计数[个/μl, M(Q₁,Q₃)]	436.8(247.9,575.4)	567.6(437.8,618.6)	344.2(239.6,457.3)	U=74.000	0.009
CD3⁺CD8⁺细胞百分比[%, M(Q₁,Q₃)]	25.5(21.2,34.4)	26.8(22.2,34.4)	24.7(18.2,34.7)	U=126.000	0.403
CD4⁺/CD8⁺比值[M(Q₁,Q₃)]	1.5(1.0,2.0)	1.3(1.1,1.7)	1.7(1.0,2.7)	U=178.000	0.403
CD3⁺/CD16⁺CD56⁺细胞计数[个/μl,M(Q₁,Q₃)]	227.8(121.3,415.0)	252.4(155.5,495.3)	193.8(105.1,393.8)	U=114.000	0.217
CD3⁺/CD16⁺CD56⁺细胞百分比[%,M(Q₁,Q₃)]	16.6(11.1,22.9)	16.7(10.4,22.7)	16.6(12.0,24.8)	U=153.000	1.000
CD3⁺CD19⁺细胞计数[个/μl, M(Q₁,Q₃)]	160.0(83.4,218.5)	174.3(145.9,217.2)	127.7(63.4,214.5)	U=108.000	0.151
CD3⁺CD19⁺细胞百分比[%, M(Q₁,Q₃)]	10.2(7.8,14.3)	10.7(8.0,12.4)	8.9(6.3,14.5)	U=133.000	0.545
CD3⁺CD45⁺细胞计数[个/μl, M(Q₁,Q₃)]	956.9(761.9,1421.6)	1293.4(923.3,1475.9)	841.0(662.8,1162.9)	U=93.000	0.052
CD3⁺CD45⁺细胞百分比[%, M(Q₁,Q₃)]	69.0(63.8,74.3)	71.3(64.5,74.1)	67.8(63.8,74.6)	U=145.000	0.832
C反应蛋白[mg/L,M(Q₁,Q₃)]	9.7(3.3,34.9)	8.6(3.0,42.7)	9.7(4.8,34.8)	U=2248.000	0.784
降钙素原[ng/ml,M(Q₁,Q₃)]	0.0(0.0,0.1)	0.0(0.0,0.2)	0.0(0.0,0.1)	U=2203.000	0.690
血红细胞沉降率[mm/1h, M(Q₁,Q₃)]	29.0(14.8,48.0)	28.0(15.5,46.0)	29.0(14.0,48.0)	U=2112.500	0.982
谷丙转氨酶[U/L,M(Q₁,Q₃)]	15.9(11.0,26.0)	18.0(11.8,27.4)	14.9(10.4,23.9)	U=1965.500	0.152
谷草转氨酶[U/L,M(Q₁,Q₃)]	30.0(23.8,38.0)	30.3(23.0,38.3)	30.0(23.9,38.0)	U=2324.000	0.903
总胆红素[μmol/L,M(Q₁,Q₃)]	10.2(7.5,13.8)	10.4(8.3,13.8)	10.1(7.5,13.8)	U=2172.000	0.591
内生肌酐清除率[ml/min, M(Q₁,Q₃)]	78.6(62.5,102.6)	75.6(62.1,99.5)	81.3(63.4,102.4)	U=2126.000	0.429
活化部分凝血活酶时间[s, M(Q₁,Q₃)]	27.8(25.2,30.7)	26.6(24.8,28.7)	28.1(26.1,32.1)	U=2890.000	0.006
血浆凝血酶原时间[s,M(Q₁,Q₃)]	11.5(10.7,12.6)	11.4(10.6,12.2)	11.7(10.8,12.8)	U=2678.500	0.072
凝血酶时间[s,M(Q₁,Q₃)]	17.4(16.4,18.3)	17.6(16.6,18.4)	17.4(16.3,18.1)	U=2193.500	0.744
心肌肌钙蛋白Ⅰ[ng/ml,M(Q₁,Q₃)]	0.05(0.02,0.09)	0.03(0.02,0.09)	0.05(0.02,0.08)	U=1897.500	0.884
乳酸脱氢酶[U/L,M(Q₁,Q₃)]	178.0(159.3,217.9)	186.4(166.0,235.5)	170.3(151.7,205.7)	U=1784.000	0.030
肌酸激酶[U/L,M(Q₁,Q₃)]	59.5(41.3,92.0)	65.0(49.0,102.5)	56.0(36.0,85.5)	U=1780.500	0.029
肌酸激酶同工酶[U/L,M(Q₁,Q₃)]	9.0(7.0,13.0)	10.5(7.5,13.1)	8.6(7.0,11.1)	U=1955.000	0.154

特征	合计(81例)	痰菌阴性组(52例)	痰菌阳性组(29例)	统计检验值	P值
年龄(岁,$\bar{x}±s$)	58.9±16.2	59.2±16.2	58.4±16.5	t=0.220	0.826
性别[例(构成比,%)]				χ²=1.348	0.246
男性	61(75.3)	37(71.2)	24(82.8)
女性	20(24.7)	15(28.8)	5(17.2)
体质量指数($\bar{x}±s$)	20.7±3.8	21.2±4.0	19.8±3.4	t=1.633	0.107
吸烟[例(构成比,%)]				χ²=0.123	0.726
是	37(45.7)	23(44.2)	14(48.3)
否	44(54.3)	29(55.8)	15(51.7)
饮酒[例(构成比,%)]				χ²=0.009	0.922
是	13(16.0)	9(17.3)	4(13.8)
否	68(84.0)	43(82.7)	25(86.2)
预后情况[例(构成比,%)]				χ²=0.273	0.601
改善	78(96.3)	51(98.1)	27(93.1)
恶化	3(3.7)	1(1.9)	2(6.9)
住院时间[d,M(Q₁,Q₃)]	10.0(7.0,13.0)	8.0(6.0,11.0)	13.5(10.8,17.0)	U=1180.500	<0.001
CT影像学恢复时间[d,M(Q₁,Q₃)]	9.0(7.0,12.0)	7.0(4.0,7.8)	11.0(8.5,19.0)	U=154.500	0.001
合并症[例(发生率,%)]
尘肺	6(7.8)	4(7.8)	2(7.7)	χ²=0.001	0.981
慢性阻塞性肺疾病	37(48.1)	24(47.1)	13(50.0)	χ²=0.060	0.807
肿瘤	2(2.6)	1(2.0)	1(3.8)		1.000^a
糖尿病	24(30.8)	15(28.8)	9(34.6)	χ²=0.271	0.603
心血管疾病	33(42.9)	25(49.0)	8(30.8)	χ²=2.342	0.126
慢性肝病	4(5.2)	3(5.9)	1(3.8)	χ²=1.987	0.159
慢性肾病	1(1.3)	0(0.0)	1(3.8)		0.338^a
首发症状[例(发生率,%)]
发热	31(38.3)	17(32.7)	14(48.3)	χ²=1.914	0.167
咳嗽	70(86.4)	45(86.5)	25(86.2)	χ²=0.002	0.967
呼吸困难	37(45.7)	19(36.5)	18(62.1)	χ²=4.890	0.027
肌肉酸痛	14(17.3)	8(15.4)	6(20.7)	χ²=0.366	0.545
咽痛	11(13.6)	6(11.5)	5(17.2)	χ²=0.144	0.704
胸闷	12(14.8)	8(15.4)	4(13.8)	χ²=0.000	1.000
消化道症状	24(29.6)	17(32.7)	7(24.1)	χ²=0.653	0.419
皮肤症状	2(2.5)	1(1.9)	1(3.4)		1.000^a
CT影像学特征[例(发生率,%)]
磨玻璃影	18(22.2)	11(21.2)	7(24.1)	χ²=0.096	0.757
斑片影	74(91.4)	46(88.5)	28(96.6)	χ²=0.689	0.407
条索影	74(91.4)	48(92.3)	26(89.7)	χ²=0.000	1.000
胸膜增厚	24(29.6)	15(28.8)	9(31.0)	χ²=0.043	0.836
结节	24(29.6)	18(34.6)	6(20.7)	χ²=1.732	0.188
淋巴结肿大	22(27.2)	12(23.1)	10(34.5)	χ²=1.224	0.269
累及双肺	62(76.5)	36(69.2)	26(89.7)	χ²=4.326	0.038
累及右肺	7(8.6)	7(13.5)	0(0.0)	χ²=2.738	0.098
累及左肺	12(14.8)	9(17.3)	3(10.3)	χ²=0.270	0.603
治疗方案[例(使用率,%)]
抗生素治疗	45(55.6)	23(44.2)	22(75.9)	χ²=7.544	0.006
中药治疗	47(58.0)	30(57.7)	17(58.6)	χ²=0.007	0.935
激素治疗	9(11.1)	4(7.7)	5(17.2)	χ²=0.888	0.346
激素治疗时间[d,M(Q₁,Q₃)]	6.0(4.0,11.0)	5.0(3.3,18.3)	7.0(6.0,11.0)	U=12.500	0.556
抗病毒治疗	10(12.3)	5(9.6)	5(17.2)	χ²=0.420	0.517
抗病毒治疗时间[d,M(Q₁,Q₃)]	7.0(5.5,12.3)	7.0(5.0,7.0)	7.0(7.0,14.0)	U=15.500	0.548
实验室检测指标
红细胞计数[×10¹²/L,M(Q₁,Q₃)]	4.1(3.7,4.5)	4.1(3.7,4.4)	4.2(3.6,4.6)	U=709.500	0.852
血红蛋白[g/L,M(Q₁,Q₃)]	122.0(106.0,132.0)	122.0(108.8,131.3)	123.0(99.0,133.0)	U=723.000	0.760
红细胞压积[%,M(Q₁,Q₃)]	36.2(32.4,39.2)	36.3(32.4,38.9)	35.8(31.9,39.5)	U=721.500	0.939
血小板计数[×10⁹/L,M(Q₁,Q₃)]	192.5(144.0,287.8)	192.5(141.0,241.8)	195.0(157.8,297.3)	U=797.500	0.483
淋巴细胞计数[×10⁹/L,M(Q₁,Q₃)]	1.0(0.7,1.6)	1.0(0.8,1.7)	1.0(0.6,1.4)	U=616.000	0.259
白细胞计数[×10⁹/L,M(Q₁,Q₃)]	5.3(3.8,7.2)	4.7(3.7,6.2)	6.3(4.4,8.4)	U=994.000	0.018^λ
中性粒细胞计数[×10⁹/L, M(Q₁,Q₃)]	3.3(2.2,4.7)	2.8(2.0,3.7)	3.7(2.9,6.2)	U=1037.500	0.005^λ
中性粒细胞百分比[%,M(Q₁,Q₃)]	64.2(52.8,73.9)	60.7(51.5,70.0)	71.3(61.9,77.7)	U=1008.500	0.012^λ
CD3⁺CD4⁺细胞计数[个/μl, M(Q₁,Q₃)]	454.7(301.3,638.6)	454.7(356.9,638.6)	361.7(247.5,709.2)	U=24.000	0.596
CD3⁺CD4⁺细胞百分比[%, M(Q₁,Q₃)]	39.1(33.4,47.7)	39.1(33.4,46.3)	41.4(34.3,47.2)	U=30.000	1.000
CD3⁺CD8⁺细胞计数[个/μl, M(Q₁,Q₃)]	344.2(239.6,457.3)	344.2(199.3,501.9)	320.7(258.0,396.1)	U=31.000	1.000
CD3⁺CD8⁺细胞百分比[%, M(Q₁,Q₃)]	24.7(18.2,34.7)	21.9(18.2,30.5)	31.5(22.5,39.1)	U=36.000	0.596
CD4⁺/CD8⁺比值[M(Q₁,Q₃)]	1.7(1.0,2.7)	1.7(1.0,2.7)	1.4(0.9,2.2)	U=26.000	0.736
CD3⁺/CD16⁺CD56⁺细胞计数[个/μl,M(Q₁,Q₃)]	193.8(105.1,393.8)	213.1(110.9,393.8)	143.2(104.8,229.6)	U=25.000	0.665
CD3⁺/CD16⁺CD56⁺细胞百分比[%,M(Q₁,Q₃)]	16.6(12.0,24.8)	16.6(12.0,29.1)	17.6(13.5,19.7)	U=26.000	0.736
CD3⁺CD19⁺细胞计数[个/μl, M(Q₁,Q₃)]	127.7(63.4,214.5)	127.7(63.4,211.8)	144.4(69.4,208.9)	U=31.000	1.000
CD3⁺CD19⁺细胞百分比[%, M(Q₁,Q₃)]	8.9(6.3,14.5)	8.9(6.4,14.5)	9.7(7.0,13.7)	U=30.000	1.000
CD3⁺CD45⁺细胞计数[个/μl, M(Q₁,Q₃)]	841.0(662.8,1162.9)	845.9(682.2,1162.9)	727.0(629.2,986.2)	U=24.000	0.596
CD3⁺CD45⁺细胞百分比[%, M(Q₁,Q₃)]	67.8(63.8,74.6)	67.6(60.2,73.6)	73.3(70.2,75.7)	U=41.000	0.307
C反应蛋白[mg/L,M(Q₁,Q₃)]	9.8(5.3,34.9)	9.0(1.4,25.8)	21.4(8.2,48.0)	U=967.500	0.009^λ
降钙素原[ng/ml,M(Q₁,Q₃)]	0.0(0.0,0.1)	0.0(0.0,0.1)	0.1(0.0,0.2)	U=789.000	0.089
血红细胞沉降率[mm/1h, M(Q₁,Q₃)]	29.0(14.0,49.0)	23.0(9.0,45.5)	38.0(25.0,60.5)	U=835.000	0.011
谷丙转氨酶[U/L,M(Q₁,Q₃)]	14.7(10.2,23.7)	14.3(10.2,23.3)	15.0(10.5,23.7)	U=716.500	0.908
谷草转氨酶[U/L,M(Q₁,Q₃)]	30.0(23.9,38.0)	31.3(24.0,38.2)	28.6(22.8,35.5)	U=625.000	0.299
总胆红[μmol/L,M(Q₁,Q₃)]	10.1(7.5,13.8)	10.0(7.3,13.5)	10.1(7.6,17.0)	U=778.000	0.614
内生肌酐清除率[ml/min, M(Q₁,Q₃)]	81.3(64.0,102.7)	79.6(63.6,102.7)	84.8(64.5,101.0)	U=700.000	0.566
活化部分凝血活酶时间[s, M(Q₁,Q₃)]	28.1(26.1,32.2)	28.6(26.3,32.5)	27.9(25.2,29.9)	U=582.500	0.178
血浆凝血酶原时间[s,M(Q₁,Q₃)]	11.7(10.8,12.8)	11.7(10.8,12.7)	11.7(10.9,12.9)	U=756.500	0.663
凝血酶时间[s,M(Q₁,Q₃)]	17.4(16.3,18.2)	17.5(16.2,18.3)	17.2(16.5,17.9)	U=637.000	0.430
心肌肌钙蛋白Ⅰ[ng/ml,M(Q₁,Q₃)]	0.05(0.02,0.08)	0.05(0.02,0.08)	0.06(0.02,0.08)	U=568.000	0.642
乳酸脱氢酶[U/L,M(Q₁,Q₃)]	171.0(152.5,206.4)	169.1(149.9,206.8)	173.0(161.0,205.0)	U=812.500	0.564
肌酸激酶[U/L,M(Q₁,Q₃)]	56.0(36.0,86.0)	60.0(40.8,92.0)	47.0(36.0,66.0)	U=613.000	0.165
肌酸激酶同工酶[U/L,M(Q₁,Q₃)]	8.6(7.0,11.2)	8.0(6.2,11.0)	8.9(8.0,13.3)	U=903.500	0.141

References 21

[1]	Tamuzi JL, Ayele BT, Shumba CS, et al. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infect Dis, 2020, 20(1): 744. doi:10.1186/s12879-020-05450-4. pmid: 33036570
[2]	Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J, 2020, 56(1): 2001398. doi:10.1183/13993003.01398-2020.
[3]	Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol, 2021, 93(4): 2385-2395. doi:10.1002/jmv.26740. pmid: 33331656
[4]	González-Domenech CM, Pérez-Hernández I, Gómez-Ayerbe C, et al. A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis. Viruses, 2021, 13(5): 931. doi:10.3390/v13050931.
[5]	Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis (Edinb), 2021, 126: 102020. doi:10.1016/j.tube.2020.102020.
[6]	Wang Q, Guo S, Wei X, et al. Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021). BMJ Open, 2022, 12(6): e059396. doi:10.1136/bmjopen-2021-059396.
[7]	Petrone L, Petruccioli E, Vanini V, et al. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis, 2021, 113 Suppl 1: S82-S87. doi:10.1016/j.ijid.2021.02.090. pmid: 33713816
[8]	Sheerin D, Abhimanyu, Peton N, et al. Immunopathogenic overlap between COVID-19 and tuberculosis identified from transcriptomic meta-analysis and human macrophage infection. iScience, 2022, 25(6): 104464. doi:10.1016/j.isci.2022.104464.
[9]	中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局综合司.新型冠状病毒感染诊疗方案(试行第十版). 国卫办医急函〔2023〕4号. 2023-01-05.
[10]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
[11]	Tiberi S, Utjesanovic N, Galvin J, et al. Drug resistant TB-latest developments in epidemiology, diagnostics and management. Int J Infect Dis, 2022, 124 Suppl 1: S20-S25. doi:10.1016/j.ijid.2022.03.026.
[12]	Hartnady Z, Krehbiel B, Stenzel A, et al. Outcomes and Clinical Characteristics of COVID-19 in Patients with Tuberculosis: A Retrospective Matched Cohort Study. Infect Dis Rep, 2023, 15(2): 204-209. doi:10.3390/idr15020021. pmid: 37102981
[13]	Udoakang AJ, Djomkam Zune AL, Tapela K, et al. The COVID-19, tuberculosis and HIV/AIDS: Ménage à Trois. Front Immunol, 2023, 14: 1104828. doi:10.3389/fimmu.2023.1104828.
[14]	Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect, 2021, 27(4): 520-531. doi:10.1016/j.cmi.2020.12.018.
[15]	Bonow RO, Fonarow GC, O’Gara PT, et al. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol, 2020, 5(7): 751-753. doi:10.1001/jamacardio.2020.1105. pmid: 32219362
[16]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506. doi:10.1016/S0140-6736(20)30183-5. pmid: 31986264
[17]	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062. doi:10.1016/S0140-6736(20)30566-3. pmid: 32171076
[18]	Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl), 2020, 133(9): 1025-1031. doi:10.1097/CM9.0000000000000744.
[19]	Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol, 2020, 17(5): 533-535. doi:10.1038/s41423-020-0402-2. pmid: 32203188
[20]	Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol, 2020, 11(1): 827. doi:10.3389/fimmu.2020.00827.
[21]	Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond), 2020, 52(12): 902-907. doi:10.1080/23744235.2020.1806353.